Lyra Therapeutics names new chief medical officer.

M2 EQUITYBITES-July 6, 2022-Lyra Therapeutics names new chief medical officer

(C)2022 M2 COMMUNICATIONS http://www.m2.com

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a US-based clinical-stage therapeutics company, announced on Tuesday that it has named Richard Nieman, MD as its new chief medical officer, effective 11 July 2022.

Dr Nieman has over 25 years of experience in drug development and medical affairs. He is a respiratory physician (pulmonologist) with deep pharmaceutical medicine experience. He has served as SVP & worldwide medical head of Immunology at Bristol Myers Squibb (BMS), head of R&D China at BMS, global medical officer & head of Medical at Teva, and head of Asia Pacific Medical at Bayer. He has headed the company's medical and health economic and outcome research (HEOR) function of 550 professionals and was a member of the Specialty Executive Team. He is a Fellow of the UK Royal College of Physicians, a visiting senior lecturer at the School of Cancer and...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT